Do glial‐reactivity and cerebral blood flow modulate cerebral glucose metabolism in Alzheimer’s disease?
Rattachement africain : gb, nl. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Alzheimer’s disease is a devastating neurodegenerative disorder with a complex pathogenesis. One main pathological feature utilised in diagnosis is neurodegeneration or neuronal injury, which is reflected in reductions in cerebral glucose metabolism measured by [18F]Fluorodeoxyglucose ([18F]FDG) positron emission tomography (PET). Here we evaluated the involvement of glial reactivity measured with magnetic resonance spectroscopy (MRS) and cerebral blood flow measured with arterial spin labelling (ASL) on [18F]FDG PET as a measure of cerebral glucose metabolism. Method 123 people living with early Alzheimer’s disease who completed baseline evaluations on the evaluating liraglutide in Alzheimer’s disease trial were enrolled. Participants completed [18F]FDG PET scans with arterial input, T1 weighted MRI, single‐voxel 1HMRS, and pulsed ASL scans at Imperial College London Clinical Imaging Facility. The Totally Automatic Robust Quantitation in NMR (TARQUIN) package was used to process MRS scans and identify the concentration of myo‐inositol within the posterior cingulate cortex (PCC), a marker of glial activation. Oxford‐ASL was utilised to process ASL and quantify cerebral blood flow in the PCC. Finally, spectral analysis was performed on the [18F]FDG PET scans to assess the cerebral metabolic rate of glucose in the PCC. Result Pearson’s correlations were performed between the cerebral metabolic rate of glucose, cerebral blood flow and glial activity measured by the level of myo‐inositol in the PCC. Increased cerebral glucose metabolism was correlated with higher myo‐inositol in this sample of Alzheimer’s disease participants. In contrast, cerebral blood flow was not associated with cerebral glucose metabolism. Conclusion Here we demonstrate that increased glial reactivity contributes to [18F]FDG PET signal in the early stages of Alzheimer’s disease. In response to early neuronal injury, astrocytes and microglia may become activated and enhance regional rates of glucose consumption. Hence, the contribution from these cells in addition to neurons should be considered in interpreting [18F]FDG PET as a measure of cerebral glucose metabolism. Interestingly, cerebral blood flow did not influence glucose metabolism. Microglia and astrocyte reactivity may contribute to an increase the cerebral glucose metabolism while neuronal loss and synaptic function may contribute to lower glucose metabolism measured by [18F]FDG in the early stages of Alzheimer's disease.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Do glial‐reactivity and cerebral blood flow modulate cerebral glucose metabolism in Alzheimer’s disease?
- Date Crossref
- 01/12/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Imperial College London pays non établi dans la noticeUniversité ou école supérieure
-
University of Edinburgh Edinburgh Dementia Prevention pays non établi dans la noticeUniversité ou école supérieure
-
University of Southampton pays non établi dans la noticeUniversité ou école supérieure
-
University College London Dementia Research Centre pays non établi dans la noticeUniversité ou école supérieure
-
UK Dementia Research Institute pays non établi dans la noticeStructure de recherche
-
South West London and St George's Mental Health NHS Trust pays non établi dans la noticeÉtablissement de santé
-
Southern Health NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
North Bristol NHS Trust pays non établi dans la noticeÉtablissement de santé
-
University of Bristol pays non établi dans la noticeUniversité ou école supérieure
-
University of Cambridge pays non établi dans la noticeUniversité ou école supérieure
-
Northamptonshire Healthcare NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
-
Lancashire Care NHS Foundation Trust pays non établi dans la noticeÉtablissement de santé
Imperial College London, Edinburgh Dementia Prevention — University of Edinburgh et University of Southampton, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.